Check patentability & draft patents in minutes with Patsnap Eureka AI!

Novel human beta 2 integrin alpha subunit

A spinal cord injury, monoclonal antibody technology, applied in animal/human protein, anti-animal/human immunoglobulin, immunoglobulin, etc., can solve the problem of unclear mechanism

Inactive Publication Date: 2005-03-02
ICOS CORP
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Interestingly, at least one CD18-specific antibody has been shown to inhibit human immunodeficiency virus type 1 (HIV-1) syncytium formation in vitro, but the exact mechanism of this inhibition is unclear [Hildreth and Orentas, Science 244:1075-1078 (1989)]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel human beta 2 integrin alpha subunit
  • Novel human beta 2 integrin alpha subunit
  • Novel human beta 2 integrin alpha subunit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Try to detect canine alpha TM1 human homologue

[0057] detection for canine alpha TM1 The cross-reactivity of the monoclonal antibody Ca11.8H2 (Moore, et al.) to human peripheral blood lymphocytes sought to identify a canine alpha TM1 human homologues. Cell preparation (usually 1×10 6 cells) were incubated with undiluted hybridoma supernatant or a purified mouse IgG-negative control antibody (10 μg / ml) in the presence of 0.1% sodium azide on ice. Bound monoclonal antibodies were detected with subsequent incubation with 6 μg / ml of FITC-conjugated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA). Stained cells were fixed with 2% w / v paraformaldehyde in phosphate buffered saline (PBS) and analyzed using a Facstar Plus fluorescence activated cell sorter (Becton Dickinson, Mountain View, CA). Typically, 10,000 cells are analyzed with logarithmic amplification to measure fluorescence density.

[0058] The results showed that Ca11.8H2 did not cross-react with ...

Embodiment 2

[0061] Affinity purified canine alpha TM1 for N-terminal sequencing

[0062] Affinity purified canine alpha TM1 To determine the N-terminal amino acid sequence for oligonucleotide probe / primer design. In short, the anti-alpha TM1 Monoclonal antibody Ca11.8H2 was coupled to Affigel_10 chromatography resin (BioRad, Hercules, CA), and proteins were separated by specific protein-protein interactions. Antibodies were coupled to the resin at a concentration of approximately 5 mg antibody per ml resin according to BioRad recommended procedures. After the coupling reaction, excess antibody was removed and the resin was blocked with three volumes of 0.1M ethanolamine. The resin was then washed with thirty volumes of phosphate buffered saline (PBS).

[0063] 25 grams of one dog spleen was homogenized in 250 ml of 25 mM Tris-HCl, pH 8.0 buffer containing 0.32 M sucrose and containing protease inhibitors. Nuclei and cellular debris were pelleted by centrifugation at 1000g for 15 min...

Embodiment 3

[0084] Large scale affinity purification of canine alpha TM1 for in-house sequencing

[0085] To provide additional amino acid sequences for primer design, purified canine α TM1 For in-house sequencing. Proteins sequenced in-house were prepared using three frozen spleens (approximately 50 grams each) and frozen cells from two partial spleens of adult dogs. 50 g of spleen was homogenized in 200-300 ml of boric acid buffer with a Waring blender. The homogenized material was diluted with 1 volume of buffer containing 4% NP-40, and the mixture was stirred gently for at least 1 hour. The resulting lysates were centrifuged at 2000 g for 20 minutes to clear the bulk of the residue and then filtered through a Corning (Corning, NY) prefilter or Corning 0.8 microfilter, and the lysate was further clarified by filtration through a Corning 0.4 microfiltration membrane system.

[0086] The spleen lysate and the antibody-coupled Affigel-10 resin described in Example 2 were combined into...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method of reducing inflammation at a site of central nervous system injury comprising administering to an individual an effective amount of an inhibitory alpha d Conjugated small molecule steps. Specifically, the central nervous system injury mentioned in the method of the present invention is spinal cord injury. made public with α d Methods of monoclonal antibody therapy for spinal cord injury.

Description

[0001] This application is a continuation-in-part of pending U.S. Patent Application Serial No. 09 / 350,259, filed July 8, 1999, which is a continuation of pending U.S. Patent Application Serial No. 09 / 193,043, filed November 16, 1998 Continuation-in-Part, 09 / 193,043 is a continuation-in-part of pending U.S. Patent Application Serial No. 08 / 943,363, filed October 3, 1997, which is a continuation-in-part of U.S. Patent Application Serial No. 08 / 605,672, filed February 22, 1996 Continuation-in-Part, 08 / 605,672, issued October 6, 1998 as U.S. Patent 5,817,515, which is a continuation-in-part of U.S. Patent Application Serial No. 08 / 362,652, filed December 21, 1994, 08 / 362,652, June 1998 Issued on the 16th as U.S. Patent 5,766,850, which is a continuation of U.S. Patent Application Serial No. 08 / 286,889, filed August 5, 1994, which was issued on November 28, 1995 as U.S. Patent 5,470,953, which is a 1993 A continuation-in-part of US Patent Application Serial No. 08 / 173,497, filed Dec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K38/00A61K39/395A61P25/00A61P37/00C07K14/705C07K16/28C07K16/42C12Q1/68G01N33/68
CPCC07K2319/00C07K16/2845G01N33/6893A01K2217/05A61K38/00A61K2039/505G01N2333/70553C07K14/70553C12Q1/6818A61P25/00A61P37/00A61K39/395
Inventor W·M·加拉丁M·范德维伦
Owner ICOS CORP
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com